糖酵解重编程的UC-MSC分泌组促进RA患者PBMC中Treg生成与naive CD4 T细胞稳定
研究将脐带间充质干细胞(UC-MSC)经寡霉素抑制氧化磷酸化重编程为糖酵解代谢,与21例类风湿关节炎(RA)患者活化PBMC共培养。重编程UC-MSC免疫抑制活性增强,经分泌组(主要为>3 kDa蛋白组分)介导,使Treg频率从16.5%升至30.2%、CD4+CD45RA+ naive T细胞从9.7%升至29.1%,并在小鼠DTH模型中减轻炎症。
要点
- 糖酵解重编程增强UC-MSC对RA患者PBMC的免疫抑制活性。
- 效应主要由分泌组中>3 kDa蛋白组分介导,支持无细胞策略。
- 共培养使Treg由16.5%升至30.2%、naive CD4 T细胞由9.7%升至29.1%。
核心结论
- 将UC-MSC代谢重编程为糖酵解可经分泌组依赖机制增强其免疫调节能力。
- 该免疫调节活性主要由>3 kDa蛋白富集组分介导,支持基于代谢与无细胞的MSC治疗策略。
研究设计与样本
- 基础研究:用寡霉素药理性抑制氧化磷酸化,将UC-MSC重编程为糖酵解代谢。
- 与21例RA患者活化PBMC在直接接触与条件培养基条件下共培养,流式细胞术分析T细胞增殖、表型与细胞周期。
- 采用迟发型超敏反应(DTH)小鼠模型评估抗炎效应,并分析UC-MSC分泌组及其蛋白组分的贡献。
主要发现
- 糖酵解重编程UC-MSC较未修饰UC-MSC免疫抑制活性增强,抑制促炎T细胞反应、促进Treg扩增并保留CD4+CD45RA+ naive T细胞。
- 上述效应伴随T细胞周期阻滞于G0期。
- 条件培养基实验显示效应主要由MSC分泌组介导,Treg频率从16.5%升至30.2%,CD4+CD45RA+ naive T细胞从9.7%升至29.1%。
- 蛋白组分贡献了大部分免疫调节活性;体内>3 kDa蛋白富集组分减轻DTH相关炎症并促进抗炎免疫反应。
关键数值与推荐
- Treg频率:16.5%升至30.2%(RA患者PBMC条件培养基共培养)。
- CD4+CD45RA+ naive T细胞:9.7%升至29.1%(同上条件)。
- 体内活性定位于>3 kDa蛋白富集组分(DTH小鼠模型)。
临床怎么用
- 提示代谢重编程可提升UC-MSC免疫调节效力,为RA的MSC治疗优化提供方向。
- 分泌组尤其>3 kDa蛋白组分是无细胞治疗策略的候选来源。
局限性
- 体外实验基于21例RA患者PBMC,样本量有限。
- 体内验证仅采用DTH小鼠模型,尚需RA疾病模型验证。
- 原文未报告临床疗效终点与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid arthritis (RA) is characterized by persistent inflammation and dysregulated T cell responses. Mesenchymal stromal cells (MSCs) have immunomodulatory properties, but their clinical efficacy remains variable. We investigated whether metabolic reprogramming of umbilical cord-derived MSCs (UC-MSCs) toward glycolysis enhances their immunoregulatory function and the underlying mechanisms. METHODS: UC-MSCs were reprogrammed toward glycolysis by pharmacologic inhibition of oxidative phosphorylation using oligomycin. Their immunomodulatory capacity was assessed in coculture with activated peripheral blood mononuclear cells (PBMCs) from 21 RA patients under direct-contact and conditioned-medium conditions. T cell proliferation, phenotype, and cell cycle were analyzed by flow cytometry. Anti-inflammatory effects were evaluated in a delayed-type hypersensitivity (DTH) murine model, and the contribution of the UC-MSC secretome and its protein fraction was investigated. RESULTS: Glycolysis-reprogrammed UC-MSCs exhibited enhanced immunosuppressive activity compared with unmodified UC-MSCs, suppressing proinflammatory T cell responses, promoting Treg expansion, and preserving CD4+CD45RA+ naïve T cells. These effects were associated with T cell cycle arrest in G0. Conditioned-medium experiments showed that these effects were largely mediated by the MSC secretome, increasing Treg frequency from 16.5% to 30.2% and enriching the CD4+CD45RA+ naïve T-cell compartment from 9.7% to 29.1%, with the protein fraction accounting for most of this immunomodulatory activity. In vivo, the >3 kDa protein-enriched fraction attenuated DTH-associated inflammation and promoted an anti-inflammatory immune response. CONCLUSION: Metabolic reprogramming of UC-MSCs toward glycolysis enhances their immunomodulatory capacity through secretome-dependent mechanisms, primarily mediated by proteins within the >3 kDa fraction, supporting metabolism-based and cell-free strategies for MSC-based therapy in RA.
引用
- Luque-Campos N, Pradenas C, Lara-Barba E, et al. The secretome of UC-MSC reprogrammed to a glycolytic metabolism promotes Treg generation and naive CD4 T cells stability in PBMC from rheumatoid arthritis patients. Arthritis Rheumatol. 2026. PMID: 42935446. doi:10.1002/art.70382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。